Last updated 10 months ago

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

825 patients around the world

Available in Spain, United States, Argentina

The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 12 weeks.

Bellus Health Inc

13Research sites

825Patients around the world

Requirements for the patient

To 80 Years

All Gender

Medical requirements

: Capable of giving signed informed consent
Refractory chronic cough (including unexplained chronic cough) for at least one year
Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose

: Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history
Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis or uncontrolled asthma
Respiratory tract infection within 4 weeks before screening
Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
History of malignancy in the last 5 years
History of alcohol or drug abuse within the last 3 years
Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus
Previous participation in a BLU-5937 trial